AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
ulipristal 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| steroidal compounds acting on progesterone receptors | 4166 | 126784-99-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Ulipristal acetate is a selective progesterone receptor modulator with antagonistic and partial agonistic effects (a progesterone agonist/antagonist) at the progesterone receptor. It binds the human progesterone receptor and prevents progesterone from occupying its receptor. The likely primary mechanism of action of ulipristal acetate for emergency contraception is inhibition or delay of ovulation.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 30 | mg | O |
| 5 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 56 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.855 | Moderate | 0.76 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.977 | Moderate | 0.76 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 44.978 | 10^-6 cm/s | Moderate | 0.76 |
| dh-clint | Dog hepatocyte intrinsic clearance | 29.580 | uL/min/10^6 cells | Moderate | 0.76 |
| dppb | Dog plasma protein binding (% unbound) | 0.400 | % | Moderate | 0.76 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 1.420 | % | Moderate | 0.76 |
| herg | hERG pIC50 | 4.780 | pIC50 | Moderate | 0.76 |
| hh-clint | Human hepatocyte intrinsic clearance | 42.364 | uL/min/10^6 cells | Moderate | 0.76 |
| hlm-clint | Human liver microsomal intrinsic clearance | 277.971 | uL/min/mg protein | Moderate | 0.76 |
| hppb | Human plasma protein binding (% unbound) | 0.600 | % | Moderate | 0.76 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK1,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 46 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2,MAP2K6,STK33 | 5 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.959 | Moderate | 0.76 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 148.594 | Moderate | 0.76 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.610 | Moderate | 0.76 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 12.162 | Moderate | 0.76 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 1.510 | % | Moderate | 0.76 |
| rh-clint | Rat hepatocyte intrinsic clearance | 204.644 | uL/min/10^6 cells | Moderate | 0.76 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 6.990 | % | Moderate | 0.76 |
| rppb | Rat plasma protein binding (% unbound) | 0.690 | % | Moderate | 0.76 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 6.339 | uM | Moderate | 0.76 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 15, 2009 | EMA | ||
| Aug. 13, 2010 | FDA | LAB HRA PHARMA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Unintended pregnancy | 256.89 | 44.30 | 45 | 630 | 7592 | 90620180 |
| Abortion spontaneous | 100.39 | 44.30 | 30 | 645 | 54026 | 90573746 |
| Vaginal haemorrhage | 74.09 | 44.30 | 21 | 654 | 31250 | 90596522 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Unintended pregnancy | 239.65 | 46.27 | 38 | 568 | 4770 | 110583923 |
| Abortion spontaneous | 102.93 | 46.27 | 26 | 580 | 34256 | 110554437 |
| Vaginal haemorrhage | 65.28 | 46.27 | 17 | 589 | 25057 | 110563636 |
| Uterine haemorrhage | 46.46 | 46.27 | 9 | 597 | 3485 | 110585208 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G03AD02 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Emergency contraceptives |
| ATC | G03XB02 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Progesterone receptor modulators |
| MeSH PA | D000080066 | Contraceptive Agents, Hormonal |
| MeSH PA | D003270 | Contraceptive Agents |
| MeSH PA | D003271 | Contraceptive Agents, Female |
| MeSH PA | D012102 | Reproductive Control Agents |
| FDA MoA | N0000191262 | Selective Progesterone Receptor Modulators |
| FDA EPC | N0000191263 | Progesterone Agonist/Antagonist |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:49323 | contraceptive drug |
| CHEBI has role | CHEBI:59826 | progestin |
| CHEBI has role | CHEBI:71027 | progesterone receptor modulator |
Related Drugs by ATC class:
G03AD Emergency contraceptives 1 drug
G03XB Progesterone receptor modulators 1 drug
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Uterine leiomyoma | indication | 95315005 | DOID:13223 |
| Postcoital contraception | indication | 268463003 | |
| Pregnancy, function | contraindication | 289908002 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.7 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 30MG | ELLA | LAB HRA PHARMA | N022474 | Aug. 13, 2010 | RX | TABLET | ORAL | 10159681 | April 13, 2030 | A METHOD FOR CONTRACEPTION COMPRISING THE STEP OF ORAL ADMINISTRATION A DOSAGE OF 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE |
| 30MG | ELLA | LAB HRA PHARMA | N022474 | Aug. 13, 2010 | RX | TABLET | ORAL | 10772897 | April 13, 2030 | A METHOD FOR CONTRACEPTION, THE METHOD COMPRISING ADMINISTERING A TABLET COMPRISING 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 120 HOURS AFTER AN UNPROTECTED INTERCOURSE |
| 30MG | ELLA | LAB HRA PHARMA | N022474 | Aug. 13, 2010 | RX | TABLET | ORAL | 9283233 | April 13, 2030 | METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE |
| 30MG | ELLA | LAB HRA PHARMA | N022474 | Aug. 13, 2010 | RX | TABLET | ORAL | 8426392 | June 12, 2030 | ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD |
| 30MG | ELLA | LAB HRA PHARMA | N022474 | Aug. 13, 2010 | RX | TABLET | ORAL | 8962603 | June 12, 2030 | METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99 |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Progesterone receptor | Nuclear hormone receptor | ANTAGONIST | IC50 | 9.70 | IUPHAR | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4030133 | VUID |
| N0000181720 | NUI |
| D09567 | KEGG_DRUG |
| 159811-51-5 | SECONDARY_CAS_RN |
| 4030133 | VANDF |
| 4030140 | VANDF |
| CHEBI:177631 | CHEBI |
| 2S0 | PDB_CHEM_ID |
| CHEMBL2103846 | ChEMBL_ID |
| CHEMBL260538 | ChEMBL_ID |
| C094854 | MESH_SUPPLEMENTAL_RECORD_UI |
| C555622 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB08867 | DRUGBANK_ID |
| 6J5J15Q2X8 | UNII |
| 1005920 | RXNORM |
| 175839 | MMSL |
| 26777 | MMSL |
| d07495 | MMSL |
| 013245 | NDDF |
| 013246 | NDDF |
| 703249005 | SNOMEDCT_US |
| 703250005 | SNOMEDCT_US |
| 703737005 | SNOMEDCT_US |
| C0300205 | UMLSCUI |
| 8367 | INN_ID |
| 13559281 | PUBCHEM_CID |
| 7460 | IUPHAR_LIGAND_ID |
| 6J5J15Q2X8 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Ella | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2835 | TABLET | 30 mg | ORAL | NDA | 28 sections |
| Ella | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5422 | TABLET | 30 mg | ORAL | NDA | 28 sections |
| Ella | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53002-1630 | TABLET | 30 mg | ORAL | NDA | 28 sections |
| Ella | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53002-2630 | TABLET | 30 mg | ORAL | NDA | 28 sections |
| Ella | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67296-1466 | TABLET | 30 mg | ORAL | NDA | 28 sections |
| Ella | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73302-456 | TABLET | 30 mg | ORAL | NDA | 28 sections |